Goldline Pharmaceutical IPO
Live Updates, GMP, Subscription Data, and Financial Details
IPO Overview
Live
Dates
May 12 to May 14 2026
Price Band
₹41 - 43
Current GMP
₹18(41.86%)
Subscription
22.35 times
IPO Details
| IPO Date | 12 to 14 May, 2026 |
| Listing Date | Tue, May 19, 2026 |
| Face Value | ₹ 10 per share |
| Price Band | ₹41 to ₹43 |
| Lot Size | 3,000 Shares |
| Sale Type | Fresh capital only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE SME |
| Total Issue Size | 27,00,000 shares (agg. up to ₹ 12 Cr) |
| Reserved for Market Maker | 1,38,000 shares (agg. up to ₹ 0.5934 Cr) Nirman Share Brokers Pvt.Ltd. |
| Fresh Issue (Ex Market Maker) | 25,62,000 shares (agg. up to ₹ 11 Cr) |
| Net Offered to Public | 25,62,000 shares (agg. up to ₹ 11 Cr) |
| Share Holding Pre Issue | 69,00,000 shares |
| Share Holding Post Issue | 96,00,000 shares |
IPO Date
12 to 14 May, 2026
Listing Date
Tue, May 19, 2026
Face Value
₹ 10 per share
Price Band
₹41 to ₹43
Lot Size
3,000 Shares
Sale Type
Fresh capital only
Issue Type
Bookbuilding IPO
Listing At
BSE SME
Total Issue Size
27,00,000 shares (agg. up to ₹ 12 Cr)
Reserved for Market Maker
1,38,000 shares (agg. up to ₹ 0.5934 Cr) Nirman Share Brokers Pvt.Ltd.
Fresh Issue (Ex Market Maker)
25,62,000 shares (agg. up to ₹ 11 Cr)
Net Offered to Public
25,62,000 shares (agg. up to ₹ 11 Cr)
Share Holding Pre Issue
69,00,000 shares
Share Holding Post Issue
96,00,000 shares
IPO Subscription Details
| Anchor | 1 |
| QIB (Ex Anchor) | 1.31 |
| NII*** | 24.46 |
| bNII (> ₹10L) | 22.52 |
| sNII (< ₹10L) | 28.25 |
| Individual Investors | 34.07 |
| Total ** | 22.35 |
Anchor
1
QIB (Ex Anchor)
1.31
NII***
24.46
bNII (> ₹10L)
22.52
sNII (< ₹10L)
28.25
Individual Investors
34.07
Total **
22.35
Day Wise Sub
| Day | QIB (Ex Anchor) | NII* | NII (> ₹10L) | NII (< ₹10L) | Individual Investors | Total |
|---|---|---|---|---|---|---|
| May 1 2 (Day 1) | 1.31 | 24.46 | 22.52 | 28.25 | 34.07 | 22.35 |
DayMay 1
2 (Day 1)
QIB (Ex Anchor)1.31
NII*24.46
NII (> ₹10L)22.52
NII (< ₹10L)28.25
Individual Investors34.07
Total22.35
Day Wise GMP
| Date | Price | GMP | Estimate List Price |
|---|---|---|---|
| 12-05-2026 | 43.00 | 18(41.86%) | 61 |
| 11-05-2026 | 43.00 | 17(39.53%) | 60 |
| 10-05-2026 | 43.00 | 16(37.21%) | 59 |
| 09-05-2026 | 43.00 | 15(34.88%) | 58 |
| 08-05-2026 | 43.00 | 8(18.60%) | 51 |
| 07-05-2026 | 43.00 | 0(0.00%) | 43 |
Date12-05-2026
Price43.00
GMP18(41.86%)
Estimate List Price61
Date11-05-2026
Price43.00
GMP17(39.53%)
Estimate List Price60
Date10-05-2026
Price43.00
GMP16(37.21%)
Estimate List Price59
Date09-05-2026
Price43.00
GMP15(34.88%)
Estimate List Price58
Date08-05-2026
Price43.00
GMP8(18.60%)
Estimate List Price51
Date07-05-2026
Price43.00
GMP0(0.00%)
Estimate List Price43
IPO Important Dates
| IPO Open | Tue, May 12, 2026 |
| IPO Close | Thu, May 14, 2026 |
| Allotment | Fri, May 15, 2026 |
| Refund | Mon, May 18, 2026 |
| Credit of Shares | Mon, May 18, 2026 |
| Listing | Tue, May 19, 2026 |
IPO Open
Tue, May 12, 2026
IPO Close
Thu, May 14, 2026
Allotment
Fri, May 15, 2026
Refund
Mon, May 18, 2026
Credit of Shares
Mon, May 18, 2026
Listing
Tue, May 19, 2026
IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 6,000 | ₹2,58,000 |
| Individual investors (Retail) (Max) | 2 | 6,000 | ₹2,58,000 |
| S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
| S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
| B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
ApplicationIndividual investors (Retail) (Min)
Lots2
Shares6,000
Amount₹2,58,000
ApplicationIndividual investors (Retail) (Max)
Lots2
Shares6,000
Amount₹2,58,000
ApplicationS-HNI (Min)
Lots3
Shares9,000
Amount₹3,87,000
ApplicationS-HNI (Max)
Lots7
Shares21,000
Amount₹9,03,000
ApplicationB-HNI (Min)
Lots8
Shares24,000
Amount₹10,32,000
Financial Information
| Period Ended | 31 Dec 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 27.40 | 26.28 | 22.93 | 19.39 |
| Total Income | 21.41 | 28.06 | 23.57 | 19.85 |
| Profit After Tax | 2.22 | 2.83 | 1.81 | 0.26 |
| EBITDA | 4.16 | 5.83 | 4.30 | 2.19 |
| NET Worth | 12.36 | 10.35 | 7.86 | 5.89 |
| Reserves and Surplus | 3.65 | 1.65 | 3.76 | 2.08 |
| Total Borrowing | 9.47 | 11.03 | 11.13 | 10.83 |
Period EndedAssets
31 Dec 202527.40
31 Mar 202526.28
31 Mar 202422.93
31 Mar 202319.39
Period EndedTotal Income
31 Dec 202521.41
31 Mar 202528.06
31 Mar 202423.57
31 Mar 202319.85
Period EndedProfit After Tax
31 Dec 20252.22
31 Mar 20252.83
31 Mar 20241.81
31 Mar 20230.26
Period EndedEBITDA
31 Dec 20254.16
31 Mar 20255.83
31 Mar 20244.30
31 Mar 20232.19
Period EndedNET Worth
31 Dec 202512.36
31 Mar 202510.35
31 Mar 20247.86
31 Mar 20235.89
Period EndedReserves and Surplus
31 Dec 20253.65
31 Mar 20251.65
31 Mar 20243.76
31 Mar 20232.08
Period EndedTotal Borrowing
31 Dec 20259.47
31 Mar 202511.03
31 Mar 202411.13
31 Mar 202310.83
Key Performance Indicator
| ROE | 21.02% |
| ROCE | 24.22% |
| Debt/Equity | 1.07 |
| RoNW | 17.99% |
| PAT Margin | 10.38% |
| EBITDA Margin | 19.41% |
| Price to Book Value |
ROE
21.02%
ROCE
24.22%
Debt/Equity
1.07
RoNW
17.99%
PAT Margin
10.38%
EBITDA Margin
19.41%
Price to Book Value
IPO Reservation
| QIB Shares Offered | 12,72,000 |
| − Anchor Investor Shares Offered | 7,32,000 |
| − QIB (Ex. Anchor) Shares Offered | 5,40,000 |
| NII (HNI) Shares Offered | 3,90,000 |
| − bNII > ₹10L | 2,58,000 |
| − sNII < ₹10L | 1,32,000 |
| Retail Shares Offered | 9,00,000 |
| Market Maker Shares Offered | 1,38,000 |
| Total Shares Offered | 27,00,000 |
QIB Shares Offered
12,72,000
− Anchor Investor Shares Offered
7,32,000
− QIB (Ex. Anchor) Shares Offered
5,40,000
NII (HNI) Shares Offered
3,90,000
− bNII > ₹10L
2,58,000
− sNII < ₹10L
1,32,000
Retail Shares Offered
9,00,000
Market Maker Shares Offered
1,38,000
Total Shares Offered
27,00,000
Information about company
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.” Its product range is divided into five segments:
The company do not manufacture products, it partner with third-party manufacturers who produce the medicines based on its market research and product specifications, ensuring quality and compliance with regulations.
All products are marketed and sold under the Goldline brand through our network of distributors , who supply to retailers and wholesalers. The company currently works with 15 manufacturers and 7 distributors , and it also support hospitals and healthcare providers with procurement and material supply.
The company sells products across the states of Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar.
Competitive Strengths:
Objectives of IPO
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
#: Issue Objects
1: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company
2: General Corporate Purposes
: Total
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App